KORU Medical Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

KORU Medical Systems şirketinin toplam hissedar öz sermayesi $17.7M ve toplam borcu $402.0K olup, bu da borç-öz sermaye oranını 2.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $27.4M ve $9.7M dir.

Anahtar bilgiler

2.3%

Borç/özkaynak oranı

US$401.99k

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.81m
Eşitlik	US$17.73m
Toplam yükümlülükler	US$9.66m
Toplam varlıklar	US$27.39m

Son finansal sağlık güncellemeleri

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Aug 29

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Sep 21

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Recent updates

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Nov 16

Impressive Turnaround At KORU Medical

Nov 06

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Aug 29

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

Jul 14

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Aug 14

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Jan 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KRMD 'nin kısa vadeli varlıkları ( $18.9M ) kısa vadeli yükümlülüklerini ( $6.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: KRMD şirketinin kısa vadeli varlıkları ( $18.9M ) uzun vadeli yükümlülüklerini ( $3.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KRMD şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: KRMD şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 2.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KRMD şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: KRMD, serbest nakit akışı her yıl % 30.3 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

KORU Medical Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Recent updates

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 17% to US$4.10

KORU Medical Systems, Inc. Raises Earnings Guidance for the Full Year 2024

Impressive Turnaround At KORU Medical

KORU Medical Systems, Inc. to Report Q3, 2024 Results on Nov 13, 2024

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Consensus estimates of losses per share improve by 20%

New minor risk - Market cap size

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

KORU Medical Systems, Inc Announces Executive Changes

KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024

KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan

KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic Drug

Consensus EPS estimates fall by 15%

KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems, Inc. Reaffirmes Financial Guidance for the Full Year of 2024

KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024

KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic

KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Consensus EPS estimates upgraded to US$0.18 loss, revenue downgraded

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

New minor risk - Market cap size

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes

KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023

High number of new directors

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023

Price target decreased by 10% to US$4.33

KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled Syringes

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

KORU Medical Systems, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$4.83

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KORU Medical Revised Revenue Guidance for the Full Year of 2022

KORU Medical Systems, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

KORU Medical Systems, Inc. Revises Earnings Guidance for the Full Year 2022

KORU Medical Systems, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems Revises Earnings Guidance for the Year 2022

Price target decreased to US$4.67

Repro Med Systems, Inc. to Report Q1, 2022 Results on May 04, 2022

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Consensus forecasts updated

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Repro Med Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

Third quarter 2021 earnings released: US$0.025 loss per share (vs US$0.006 profit in 3Q 2020)

Price target decreased to US$4.67

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Second quarter 2021 earnings released: US$0.025 loss per share (vs US$0.027 loss in 2Q 2020)